Short title: Uterine relaxants and embryo transfer
The effect of peri-implantation administration of uterine relaxing agents in assisted reproduction treatment cycles: a systematic review and meta-analysis embryo transfer has been strongly linked to lower pregnancy rates (Kovacs, 1999 , Schoolcraft et al., 2001 . It has been shown that difficult embryo transfer stimulates uterine junctional zone contractions (Lesny et al., 1998) . This has been postulated to lead to nonadherence of the embryo(s) to the endometrium, expulsion of the embryos from the uterine cavity shortly after embryo transfer (Lesny et al., 1998; Mansour et al., 1990; Lesny and Killick, 2004) , or both. Furthermore, it has also been shown in normal fertile women that sub-endometrial peristalsis of the junctional zone myometrium progressively increases during menstrual cycle reaching a peak at time of ovulation with the pattern changing from predominantly ante-grade (fundo-cervical) in the menstrual and proliferative phase to retrograde (cervico-fundal) or opposing contractions in the early luteal phase (Lyons et al., 1991; van Gestel et al., 2003) . The frequency of sub-endometrial peristalsis has been shown to be higher in ovarian stimulation cycles compared with natural cycles but generally follows the same pattern as in natural cycles (Lesny et al., 1998; Zhu et al., 2012) . Fanchin et al., showed that the pregnancy and implantation rates correlate negatively with the frequency of these contractions. Clinical , ongoing pregnancy and implantation rates decrease significantly in a stepwise manner with increasing frequency of uterine contractions at time of embryo transfer (Fanchin et al., 1998) . The same findings has been reported in a small study in natural cycles (Jland et al., 1997) . These findings from previous studies suggest that women with a background increase in the sub-endometrial peristalsis may have further increase in the frequency of contractions if embryo transfer is traumatic, decreasing the implantation potential. To decrease this detrimental impact of sub-endometrial hyper-peristalsis it is
Page 3 of 44 imperative to exercise utmost care by performing gentle atraumatic embryo transfer aiming to minimize trauma to the endometrium and avoid touching the uterine fundus.
The practitioner's ability to perform atraumatic embryo transfer and other patient-related factors such as endometriosis (Bulletti et al., 2002) or the presence of fibroids (Yoshino et al., 2010) may also affect uterine contractions. It has, therefore, been suggested that using pharmacological agents that inhibit uterine contractions around the time of embryo transfer may lead to an improvement in implantation and pregnancy rates. The potential candidate agents to exert this effect include: oxytocin receptor antagonists (ORA); these drugs act by antagonising naturally circulating and locally synthesized oxytocin as well as vasopressin at their receptors in the myometrium promoting uterine relaxation (Pierzynski, 2011);  prostaglandin synthetase (cyclooxygenase) inhibitors (PGSI); these drugs act by reducing levels of various prostaglandins such as PGF2 alpha, PGE2 and thromboxane A2, which are implicated in the induction of myometrial contractions in non-pregnant and pregnant uteri (Hagenfeldt, 1987; Olson et al., 2003; Marjoribanks et al., 2010) ; nitric oxide donors; these drugs are potent smooth muscle relaxants which act by increasing levels of nitric oxide and nitrites in the myometrium. This helps with vasodilatation and may help by inducing relaxation of the smooth muscles of the myometrium as shown in pregnancy (Lees et al., 1999; Bisits et al., 2004) ; beta-adrenergic receptor agonists; these drugs act by stimulating beta-adrenergic receptors in the myometrium, promoting the relaxation of the smooth muscle in cases of preterm labour (Leveno et al., 1986) and in the non-pregnant uterus (Fedorowicz et al., 2012) ; anti-cholinergic agents; these drugs act by antagonising the effect of acetylcholine at the muscarinic receptor promoting relaxation of the myometrial smooth muscles (Nakai et al., 2008; Kido et al., 2009) ; and calcium channel blockers; these drugs inhibit the influx of calcium ions through the cell membranes of smooth muscle, inhibiting
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Many randomized controlled trials (RCTs) have been conducted to evaluate the efficacy of these drugs when administered in the peri-implantation period of assisted reproduction technique cycles (Shaker et al., 1993; Tsirigotis et al., 2000; Ohl et al., 2002; Pinheiro et al., 2003; Farzi, 2005; Bernabeu et al., 2006; Firouzabadi RD, 2007; Dal Prato and Borini, 2009; Moraloglu et al., 2010; Hanevik et al., 2012; Zargar, 2013; Ng et al., 2014) . The results of these trials, however, have been conflicting. Consequently, their use in routine clinical practice within assisted reproduction treatment is not recommended. The aim of our study was to conduct a systematic review to identify all relevant RCTs and summarize the effect of these drugs on live birth and clinical pregnancy rates after assisted reproduction technique cycles as well as the safety of these medications.
<A>Materials and methods
The population of interest for our review were women undergoing assisted reproduction treatment cycles. The intervention of interest was administration of uterine relaxant drugs during the peri-implantation period of the assisted reproduction technique cycle. The periimplantation period was defined as the period spanning from the day of oocyte retrieval until 3 days after embryo transfer in assisted reproduction technique cycles in humans, as this is the period when early events of the implantation process take place. The comparator intervention was placebo, no treatment or an alternative type of uterine relaxant drug. The primary outcome of interest was live birth rate. Secondary outcomes were clinical pregnancy rate, biochemical pregnancy rates, spontaneous abortion rates (including both biochemical pregnancy losses and clinical spontaneous abortions), ectopic pregnancy rates and multiple pregnancy rates. We also sought to identify any reports of side-effects or serious reactions to the agents used in the included trials to assess any potential harm.
<B>Eligibility criteria
Studies were included if they were RCTs reporting on the use of any of the uterine relaxing agents in the peri-implantation period. Case reports, observational cohort studies, retrospective studies and non-randomized trials were excluded. Studies reporting only on surrogate outcomes (i.e. frequency of uterine contractions or patient discomfort) without reports on clinically relevant outcomes (i.e. clinical pregnancy rate, on-going pregnancy rate or live birth rate) were also excluded.
<B>Search and study selection A literature search of multiple databases; MEDLINE (1978 ( -2014 ( ), Embase (1978 ( -2014 , Two independent reviewers (MK and RD) selected the studies. The titles and abstracts were scrutinized, and the decision for inclusion or exclusion was made according to the predefined inclusion criteria. The two reviewers were not blinded to the full manuscript data. Any disagreements between the two reviewers were resolved by arbitration by a third reviewer (AC). The full manuscripts of the titles and abstracts that were considered to be relevant for inclusion were then obtained. In the case of duplicate publication, then the most recent and complete versions were selected. The full manuscripts were then examined and data were extracted by the same two independent reviewers. <B>Validity assessment Two reviewers (MK and RD) assessed the included manuscripts for validity using the quality criteria recommended by Cochrane Handbook for Systematic Reviews of Interventions (Higgins, 2011) . These included method and adequacy of randomization, achievement of allocation concealment (to assess selection bias), blinding of participants (to assess for performance bias) and assessors of outcomes (to assess for detection bias) and adequacy of follow-up (to assess for attrition bias) and reporting of all relevant outcomes (to assess for reporting bias). Assessment for publication bias in the included studies for the outcome of clinical pregnancy was made using assessment for the symmetry of the funnel Plot (Supplementary Figure 1) and Egger's test, and with the Bias statistic for the test 1.12 95% CI -0.7 to 2.96; P = 0.2 (Egger et al., 1997) . Another assessment of publication bias for effect of small studies using Harbord modification of Egger's test showed bias statistic of 1.1 and 95% CI of -0.67 to 2.87 (Harbord et al., 2006) Both tests and the symmetry of the funnel plot indicating no evidence of publication bias. The same methodology for detecting publication bias could not be carried out owing to the small number of studies reporting on live birth.
Meta-analysis of the results of the reported outcomes was carried out using Review Manager (RevMan version 5.3 for Windows) software from the Cochrane collaboration. Summary of effect size was presented using relative risk and random effects model. Assessment for statistical heterogeneity was made using I 2 , with a value above 50% indicating substantial heterogeneity. The PRISMA group guideline for reporting of systematic reviews (Moher et al., 2009 ) was used for compiling this systematic review.
It was decided a priori that, as the agents included in this review belong to different classes of pharmacological agents, it would not be appropriate to reach a practice recommendation from pooling findings of all the included studies in a single meta-analysis. Therefore, separate meta-analyses were conducted where feasible for each class of drugs.
To conclude and recommend from the appraised evidence, The Grading of Recommendations Assessment, Development and Evaluation (GRADE) Working Group methodology for assessment of the strength of treatment effect and quality of evidence was used for all uterine relaxing agents and for individual groups of medications. This was done with the use of GRADE pro software available online from the GRADE working group (Guyatt et al., 2008) .
<A>Results
The literature search yielded a total of 2000 potentially relevant citations. After screening of titles and abstracts, and removal of duplicates, 1931 citations were excluded, as they clearly did not meet the inclusion criteria, and the full texts for 69 citations were assessed. Of these 69 articles, 52 were excluded as they did not satisfy our inclusion criteria (Figure 1 ). Of these 52 studies, four were non-relevant RCTs and three were RCTs reporting only on uterine contractions, 23 were prospective observational cohort studies, eight were retrospective cohort studies, four were case reports, four were narrative reviews, three were animal studies, two were systematic reviews that were not relevant and one was a relevant systematic review but only available as poster presentation for use of oxytocin antagonists.
Seventeen studies were eligible for inclusion in our review. These studies included 3546
patients. The characteristics of the 17 included studies are presented in Table 1 . The publication dates of the 17 studies that were included ranged between 1993 and 2014.
Sample sizes varied from 27 to 800 participants. Two studies investigated the use of oxytocin receptor antagonists (atosiban) in the peri-implantation period (Moraloglu et al., 2010; Ng et al., 2014) . Four studies investigated the use of beta adrenergic receptors agonists (Tsirigottis et al., 2000; Pinheiro et al., 2003; Rabiee et al., 2011; Hanevik et al., 2012) . Seven studies investigated the use of prostaglandin synthetase inhibitors (Moon et al., 2004; Bernabeu et al., 2006; Asgharnia et al., 2007; Firouzabadi et al., 2007; Dal Prato et al., 2009; Sohrabvand et al., 2009; Sohrabvand, 2014) . Three studies reported the findings of trials investigating the use of the nitric oxide donor in the form of nitroglycerin patch (Shaker et al., 1993; Ohl et al., 2002; Farzi et al., 2005) and two studies investigated the use of the antimuscarinic agent Hyoscine (Sohrabvand et al., 2009; Zargar, 2013) .
The search did not yield any relevant studies reporting on the use of calcium channel blockers; however, a registered trial for the use of nifedipine in the peri-implantation period in frozen embryo transfer cycles was identified. This study has not yet started recruiting (Meir, 2014) .
The results of the Cochrane quality assessment for the included trials are presented in Table   2 , Figure 2 and Supplementary Tables 2-5. The quality of the included studies was generally low. The methods for randomization were unclear or inadequate in 11 out of the 17 included trials. Allocation concealment was inadequate or unclear in 13 trials. Participant blinding was lacking or unclear in nine trials. Assessor blinding was lacking or inadequately described in 13 trials. In four of the 17 studies, follow-up was incomplete or a large number of participants dropped out after recruitment, and reporting of clinically relevant outcomes was incomplete in 15 out of the 17 trials.
<B>Live birth rate
Only four studies (totalling 1317 patients) reported on the outcome of live birth. One study compared oxytocin receptor antagonist atosiban with no treatment (Ng et al., 2014) . This study did not show any statistically significant effect on live birth rate, with relative risk of 1.05 (95% CI 0.87 to 1.25). One study (Hanevik et al., 2012) compared beta adrenergic receptor agonist versus no treatment. This study found no significant effect with a relative risk of 0.85 (95% CI 0.60 to 1.20) for live birth. Two studies compared nitric oxide donor with no treatment (Ohl et al., 2002; Farzi et al., 2005) , and showed a relative risk of 1.11
(95% CI 0.68 to 1.80) for live birth showing a non-significant effect (Figure 3 ).
<B>Clinical pregnancy rate
Thirteen studies reported on the outcome of clinical pregnancy rate with a total sample size of 2760 patients. Only one study reporting on the use of the anticholinergic agent Hyoscine (Zargar et al., 2013) showed a significant beneficial effect. This study gave a relative risk of 2.33 (95% CI 1.15 to 4.74). This was the only study reporting on clinical pregnancy outcome after the use of anticholinergic drugs, and included only small number of patients. Two studies reported on the use of ORA (Moraloglu et al., 2010; Ng et al., 2014) . Meta-analysis of these two studies gave a pooled relative risk of 1.26 (95% CI 0.85 to 1.87) with no detectable statistically significant effect (Figure 4) . Four studies investigated the use of Comment [S1]: Author: it is usual to use generic drug names. should the generic be used here (hyoscine butylbromide)?
PGSI (Moon et al., 2004; Bernabeu et al. 2006; Firouzabadi et al., 2007; Dal Prato et al. 2009 ). Pooling of these four studies gave a relative risk of 1.36 (95% CI 0.87 to 2.11), with no statistically significant effect. Statistically significant heterogeneity was found in the two meta-analyses for oxytocin receptor antagonists (I 2 = 73%; P = 0.05) prostaglandins synthetase inhibitors ( I 2 = 77%; P = 0.004).
Other classes of uterine relaxing agents also did not show statistically significant effect in clinical pregnancy rate compared with placebo. Three studies (Tsirigottis et al., 2000; Pinheiro et al., 2003; Hanevik et al., 2012) reported on effect of beta adrenergic receptor agonist on clinical pregnancy rate. Pooling of the findings of these studies showed a relative risk of 0.99 (95% CI 0.59 to 1.66) (Figure 4 ). Three studies (Shaker et al.,1993; Ohl et al., 2002; Farzi et al., 2005) <B>Other secondary outcomes
Ten studies reported on the outcome of biochemical pregnancy rate, with one study (Sohrabvand et al. 2009 ) reporting on more than one drug (Supplementary Figure 3) . No significant effect was found on biochemical pregnancy rate for any of the groups of uterine relaxants with RR 1.10 (95% CI 0.96 to 1.25), 0.93 ( 95% CI 0.69 to 1.26), 0.88 (95% CI 0.34 to 2.23), 1.07 (95% CI 0.74 to 1.55) and 1.71 (95% CI 0.92 to 3.19) for the ORA (Ng et al., 2014) , PGSI (Bernabeu et al., 2006; Firouzabadi et al., 2007; Dal Prato et al., 2009; Sohrabavand et al., 2009; Sohrabavand et al., 2014) beta-adrenergic receptor agonists (Rabiee et al., 2011) , nitric oxide donors (Ohl et al., 2002; Farzi et al., 2005) and antimuscarinic agents (Sohrabavand et al., 2009; Zargar et al., 2013) , respectively.
Nine studies reported on the spontaneous abortion rate (Supplementary Figure 4) . The meta-analyses on spontaneous abortion rates showed no statistically significant difference between the intervention and control groups in any of the uterine relaxants groups with RR 0.95 (95% CI 0.64 to 1.40), 0.57 (95% CI 0.27 to 1.22), 0.60 (95% CI 0.15 to 2.42) and 0.89 (95% CI 0.40 to 1.99) for ORA (Moraloglu et al. 2010; Ng et al., 2014) , PGSI (Bernabeu et al., 2006; Firouzabadi et al., 2007; Dal Prato et al., 2009) , B adrenergic receptor agonists (Pinheiro et al., 2003; Hanevik et al., 2012) and nitric oxide donors (Ohl et al., 2002; Farzi et al., 2005) , respectively.
Only three studies reported on the outcome of ectopic pregnancy; one study reporting on oxytocin antagonist (Ng et al., 2014) , one on prostaglandin synthetase inhibitors (Dal Prato et al.,2009 ) and one study on nitric oxide donors (Ohl et al., 2002) . No statistically significant difference was found in the incidence of ectopic pregnancy in any of these individual studies between those that received uterine relaxing agents compared with no treatment with RR and 95 % CI of 0.82 (0.34 to 1.98), 0.95 (0.06 to 14.13) and 0.56 (0.05 to 5.89) for the three studies, respectively.
Five studies reported on the outcome of multiple pregnancy; two studies on the use of oxytocin receptor anatgonists (Moraloglu et al., 2010; Ng et al., 2014) , two studies on the use of prostaglandin synthetase inhibitors (Bernabeu et al., 2006; Firouzabadi et al., 2007) and one on the use of nitric oxide donors (Ohl et al., 2002) (Supplementary Figure 5) . The pooled RR and corresponding 95% CI were 0.86 (0.66 to 1.13) and 1.06 (0.57 to 1.97) for the ORA and PGSI respectively (Supplementary Figure 5) . The RR and 95% CI for the study on nitric oxide donor was 0.95 (0.22 to 4.14).
No serious side-effects were reported in any of the trials included in the review ( Table 1) .
The study by Ng et al., (2014) , which used the oxytocin antagonist atosiban reported a higher rate of congenital abnormalities in the treatment group (3.2% compared with 1.6% in the placebo group).
Using the GRADE approach for appraising the quality of included studies and effect size reported on the meta-analyses of various groups of uterine relaxants, we have shown that the current evidence for all groups showed non -significant effect based on very weak evidence (Table 3 and Supplementary Tables 2-5) (Guyatt et al., 2008) .
<A>Discussion
This systematic review sought to summarize the current evidence for the use of different classes of uterine relaxants at the peri-implantation period in during assisted reproduction.
Overall, the systematic review and meta-analyses shows that the identified evidence does not support the routine clinical use of these agents in assisted reproduction treatment cycles.
Rigorous RCTs still need to be conducted, as the quality of the included studies was generally low with significant clinical and statistical heterogeneity in most meta-analyses.
<B>Oxytocin receptor antagonists
In the meta-analyses for the ORA, although there was a no statistically significant effect on live birth and clinical pregnancy rates, the number of patients included in the trials on ORA was 980 patients, which is underpowered to identify significant difference in live birth or clinical pregnancy rate at the set statistical significance limits. Thirty more clinical pregnancies occurred in the arm using oxytocin antagonist compared with placebo or no treatment. Although the 95% confidence interval for the clinical pregnancy outcome was not statistically significant, the pooled point estimate of the risk ratios for clinical pregnancy rates was 1.26.
The oxytocin receptor antagonist used in the trials in this review was atosiban, a mixed vasopressin and oxytocin antagonist and its use was limited to 2.5 h at the time of embryo transfer. Whether the use of a more selective oxytocin receptor antagonist such as barusiban, a longer duration of use in the peri-implantation period, or both, might show a greater beneficial effect remains to be seen. The role of ORA in patients with recurrent implantation failure is still unclear. It has been shown in an observational study that ORA are beneficial in cases of recurrent implantation failure where cryopreserved embryos were transferred in a hormonal replacement cycles (Lan et al., 2012) . The trial by Ng et al. (2014) did not report a statistical increase in clinical pregnancy rate or live birth rate in patients with repeated cycles, although the authors cautioned against extrapolating this to patients with recurrent implantation failure. The result of an RCT registered in the Clinicaltrials.gov recruiting for the use of ORA in patients with repeated implantation failure is awaited (NCT01673399) (Decleer, 2015) .
The disadvantage of oxytocin receptor antagonists is the financial cost. It also requires intravenous infusion and carries the potential for serious side-effects. These include pulmonary oedema, which has been reported in obstetric populations using atosiban for tocolysis (Donders et al., 2008; Fernandez et al., 2011) . In this review, no serious side-effects of atosiban or other classes of the drugs were reported.
<B>Oral and transdermal uterine relaxants
The use of oral or transdermal agents is generally more appealing to patients and clinicians.
In this review, the only oral agent that showed a significant effect on clinical pregnancy was the anticholinergic agent, hyoscine. This was, however, based on single clinical trial, which included a relatively small number of patients with low quality assessment grading and no reporting on the primary outcome of live birth rate (Zargar, 2013) . Another small trial showed improvement of biochemical pregnancy rate with hyoscine but no clear data on clinical pregnancy rate (Sohrabvand et al., 2009) . Therefore, caution must be taken when drawing any definitive conclusions for the use of these agents in routine clinical practice.
No statistically significant effect was found on live birth or clinical pregnancy from metaanalyses of other oral or transdermal agents. In the only RCT that exclusively included patients with recurrent implantation failure, however, a statistically significant effect was reported on clinical and ongoing pregnancy rate in the treatment arm using ritodrine (Tsirigotis et al., 2000) .
Interestingly we did not identify any studies that investigated the effectiveness of calcium channel blockers. A RCT has been egistered in clinicaltrials.gov (NCT02072291) that has not started recruiting yet and will investigate the use of nifedipine on uterine contractility and pregnancy rate in frozen embryo replacement cycle (Meir, 2014) . The calcium channel blockers might be a suitable alternative oral agent to ORA as the voltage and ligand gated calcium channels are more ubiquitous structures in the smooth muscle membranes of the myometrium (Sanborn, 2000) compared with the oxytocin receptors, with ORA exerting their actions mainly through paracrine factors including prostaglandins rendering them functionally redundant especially in the non-pregnant uterus (Ivell et al., 2001) Reassuringly, our review showed no increase in the incidence of adverse fertility outcomes.
The relative risks for spontaneous abortion, ectopic pregnancy rate and multiple pregnancy rate were not significantly different between the treatment and control groups. No major side-effects were reported from any of the agents studied in this review. Although a higher rate of congenital abnormalities was reported in the ORA treatment arm in one of the trials compared with placebo, the number reported was too small to allow conclusions to be drawn.
Furthermore, the rate of congenital abnormalities reported was not markedly different from the generally expected congenital abnormalities in pregnant women, and the ORA was used for a short period before the actual implantation would have occurred, casting further doubt on a cause and effect relationship.
<B>Strengths and weaknesses
The strengths of this review mainly lie in its extensive and rigorous search strategy.
Systematic searches were conducted on multiple healthcare literature databases without language restriction. There was also no evidence of publication bias. The main limitation of this review is the low quality of the included studies. Most studies were of relatively small sample size to enable the authors to detect a clinically important minimal difference in live birth rate and other important outcome. The included studies were also not statistically heterogeneous, which would limit the interpretation of our findings. The significant heterogeneity detected in these trials can be partially explained by different inclusion and exclusion criteria among included trials with differences in dose, duration and type of uterine relaxants used. Most of the trials had one or more of element of bias as shown in the quality assessment tables (Tables 2, 3 and Supplementary Tables 2-5 ). This tends to overestimate the treatment effect limiting confidence in the findings. This has been reflected in the very low grading of the quality of evidence from the included trials, as appraised using the GRADE approach, owing to serious methodological shortfalls, e.g lack of allocation concealment or blinding.
Subgroup analyses could not be carried out owing to lack of available data reporting exclusively on certain groups of patients, e.g recurrent implantation failure, endometriosis.
Sensitivity analyses and meta-regression to adjust for effect of confounding variables was not deemed necessary, as most analyses did not show statistically significant effects.
Another important weakness in the included studies was the general lack of power to detect minimally important difference in primary outcome even after pooling studies within groups, e.g. the predicted sample size required to detect a minimally significant effect of 5% improvement in live birth assuming a background rate of 35% will be nearly 2942 patients (1471 patients in each group) for a study with a power of 0.8 and statistical significance set at 0.05. This sample size was not achieved in any of the included meta-analyses indicating possibility of false negative findings (Type II error).
In conclusion, insufficient evidence is currently avaailble to support the use of uterine relaxant agents around the time of embryo transfer in routine clinical practice. Given the methodological short comings of the current evidence, however, larger robust RCTs are clearly needed to investigate the usefulness of these agents if any (in particular, anticholinergic agents, oxytocin receptor antagonists and calcium channel blockers). It is possible that careful patient selection for the use of these agents might show greater benefit in future RCTs, e.g. patients who reported pain after previous embryo transfer, those where difficult embryo transfer is anticipated or patients with adenomyosis/endometriosis. With better scanning techniques and equipment, uterine hyper-peristalsis might be more readily detectable. This would allow the improved identification of patients who might benefit from these agents.
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